Drug
Deferiprone clinical trials
Also written L1.
- studies test it
- 43
- open now
- 3
- in phase 3
- 10
- first study started
- 2000
Keep track of what changes. Save the Deferiprone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- L1
- 6
Combined with it in one product
Studies by the year they started
43 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 17
- Phase 3
- 10
- Phase 4
- 9
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 22
ApoPharma (18) · University Hospital, Lille (5) · Ain Shams University (3) · Neuroscience Trials Australia (1) · Chiesi Canada Corp (1) · Consorzio per Valutazioni Biologiche e Farmacologiche (1) · Imperial College London (1) · Children's Hospital of Philadelphia (1)
Often tested with
Tested in the same studies.
Deferoxamine (5) · Deferasirox (2) · Moxifloxacin (1) · Diarylheptanoids (1) · Acetylcysteine (1) · Vitamin E (1) · Alpha-Tocopherol (1) · Blood Transfusion (1)
Studies
Open first, then newest update. How each study uses Deferiprone is read from its arms, and is right about nine times in ten.
Testing it · 43
- Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsRecruitingPhase 2Rohan DharmakumarNCT05604131Written as Deferiprone Tablets
- Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaRecruitingPhase 2Amit LotanNCT07759895Written as Deferiprone (DFP)
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingPhase 2Inova Health Care ServicesNCT07023666Written as Deferiprone
- Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedPhase 2/3University Hospital, LilleNCT00943748Written as deferiprone
- Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNot applicableUniversity Hospital, LilleNCT02880033Written as deferiprone
- Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedPhase 2University Hospital, LilleNCT02164253Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedPhase 2University Hospital, LilleNCT02655315Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisCompletedPhase 2/3University Hospital, LilleNCT03293069Written as Deferiprone
- Deferiprone to Delay Dementia (The 3D Study)CompletedPhase 2Neuroscience Trials AustraliaNCT03234686Written as Deferiprone 600mg delayed release tablets
- Study of Parkinson's Early Stage With DeferiproneCompletedPhase 2ApoPharmaNCT02728843Written as Deferiprone
- Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedPhase 4Chiesi Canada CorpNCT03591575Written as Deferiprone oral solution
- Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedPhase 4ApoPharmaNCT02443545Written as Deferiprone
- Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)Status unknownPhase 2Ente Ospedaliero Ospedali GallieraNCT00907283Written as Deferiprone
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedPhase 4ApoPharmaNCT02041299Written as Deferiprone
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsCompletedPhase 3Consorzio per Valutazioni Biologiche e FarmacologicheNCT01825512Written as Deferiprone
- Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationCompletedPhase 3ApoPharmaNCT02174848Written as Deferiprone oral solution
- Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentWithdrawnPhase 3CorMedixNCT01391520Written as deferiprone
- A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedPhase 2Imperial College LondonNCT01539837Written as Deferiprone 20mg
- Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)CompletedPhase 3ApoPharmaNCT01741532Written as Deferiprone oral solution
- Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedPhase 1/2Children's Hospital of PhiladelphiaNCT01709032Written as Deferasirox and deferiprone
See all 43 studies that test Deferiprone →
Given in every arm · 4 — Deferiprone is usual care beside what is tested
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac DiseasesTerminatedPhase 2Carelon ResearchNCT00115349Written as Deferiprone (L1)
- Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based TherapyStatus unknownPhase 2/3Hadassah Medical OrganizationNCT02882477Written as Deferiprone
- Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent PatientsCompletedPhase 2LipomedNCT00349453Written as Deferiprone (L1)
- Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia MajorCompletedPhase 4Ospedale MicrocitemicoNCT00800761Written as Deferoxamine and Deferiprone
Codes
What other systems call Deferiprone · ClinicalTrials.gg INT006740
- MeSH (NLM) D000077543DeferiproneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2BTY8KH53LDEFERIPRONEConfirmed FDA, NLM, Wikidata
- RxNorm 11645Confirmed FDA, Wikidata
- Wikidata Q749664deferiproneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73030DeferiproneOne source FDA
- DrugBank DB08826One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077543 | Deferiprone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2BTY8KH53L | DEFERIPRONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 11645 | — | Confirmed FDA, Wikidata |
| Wikidata | Q749664 | deferiprone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73030 | Deferiprone | One source FDA |
| DrugBank | DB08826 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.